3-(氯磺酰基)丙酸甲酯 | 15441-07-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 磺酰卤
• 中文名称: 3-(氯磺酰基)丙酸甲酯
• 中文别名: 3-氯磺酰丙酸甲酯
• 英文名称: methyl 3-(chlorosulfonyl)propanoate
• 英文别名: 3-chlorosulfonylpropionic acid methyl ester；2-carbomethoxyethane-sulfonyl chloride；methyl 3-chlorosulfonylpropanoate
• CAS: 15441-07-3
• 化学式: C₄H₇ClO₄S
• mdl: MFCD07339056
• 分子量: 186.616
• InChiKey: LWJZGJNMJBUUMC-UHFFFAOYSA-N

物化性质

• 沸点：
  110-113 °C(Press: 4 Torr)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2915900090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
• 危险品运输编号：
  3265
• 危险性描述：
  H314
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-(chlorosulfonyl)propanoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-(chlorosulfonyl)propanoate
CAS number: 15441-07-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H7ClO4S
Molecular weight: 186.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(氯磺酰基)丙酸甲酯 在 碳酸氢钠 、 sodium sulfite 作用下， 以 水 为溶剂， 反应 4.0h， 生成 3-甲氧基-3-氧代丙烷亚磺酸钠
  参考文献：
  名称：

  铜催化的喹啉N-氧化物与亚磺酸钠的C2-磺酰化脱氧反应

  摘要：

  在自由基引发剂K 2 S 2 O 8的存在下，开发了出乎意料的Cu催化的喹啉N-氧化物的C2-磺酰化脱氧反应，该反应使用亚磺酸钠作为磺酰基偶联剂。机理研究表明，该反应通过类似Minisci的自由基偶联步骤进行，从而得到具有良好化学收率的磺酰化喹啉。

  DOI：

  10.1021/acs.orglett.6b02289
• 作为产物：
  描述：

  3-sulfo-propionic acid methyl ester 在 氯化亚砜 作用下， 生成 3-(氯磺酰基)丙酸甲酯
  参考文献：
  名称：

  Restricted Rotation in Aryl Amines. VIII. Ring Nitrogen Derivatives of Diaminomesitylene

  摘要：

  DOI：

  10.1021/ja01157a036

文献信息

• [EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097944A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式(I)和式(II)的化合物，其药用盐，任何上述化合物的立体异构体，或它们的混合物是APJ受体的激动剂，并且在治疗心血管和其他疾病方面有用。式(I)和式(II)的化合物具有以下结构：(I); (II)。中间体(V)也被要求。
• [EN] COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DE GPR119
  申请人：IRM LLC

  公开号：WO2009038974A1

  公开（公告）日：2009-03-26

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

  这项发明提供了化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与GPR119活性相关的疾病或紊乱的方法。
• 5-HT RECEPTOR MODULATORS
  申请人：Kapadnis Prashant Bhimrao

  公开号：US20130053372A1

  公开（公告）日：2013-02-28

  The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

  本发明涉及式(I)化合物，用于治疗由5-羟基色胺（血清素）受体IB（5-HT1B）介导的疾病，例如血管疾病、癌症和CNS疾病。本发明还提供了治疗这些疾病的方法，以及用于治疗的化合物和组合物等。
• Palladium(0)-Catalyzed Carbonylative Synthesis of <i>N</i>-Acylsulfonamides via Regioselective Acylation
  作者：Luke S. Schembri、Jonas Eriksson、Luke R. Odell

  DOI：10.1021/acs.joc.9b00740

  日期：2019.6.7

  a mild and convenient palladium(0)-catalyzed synthesis of N-acylsulfonamides via the carbonylative coupling of sulfonyl azides and electron-rich heterocycles. The reaction proceeds via in situ generation of a sulfonyl isocyanate followed by regioselective acylation of an indole or pyrrole nucleophile. This approach has been used to synthesize 34 indole- and pyrrole-substituted N-acylsulfonamides in

  N-酰基磺酰胺代表了重要的羧酸生物等排体，可实现更大的分子精细化和增强的氢键能力。在本文中，我们提出了一种温和且方便的经由磺酰叠氮化物和富电子杂环的羰基偶合的钯（0）催化合成N-酰基磺酰胺。该反应通过原位产生磺酰基异氰酸酯，然后对吲哚或吡咯亲核试剂进行区域选择性酰化而进行。该方法已用于合成34个吲哚和吡咯取代的N-酰基磺酰胺的产率高达95％。重要的是，该方法是无配体的，并且与异位固体CO源相容，并且仅需要稍微升高的温度，这使其成为制备这一重要类别化合物的极具吸引力的方法。这项研究进一步研究了用碳11标记N-酰基磺酰胺的可能性，以促进生物学评估和正电子发射断层扫描的体内研究。
• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS MÉTHODES D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2021127499A1

  公开（公告）日：2021-06-24

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g, protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g, a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。